Head & Neck trials now recruiting

TROG 14.03 (EORTC 1219) - the aim of this study is to determine whether the addition of nimorazole to the standard treatment (radiotherapy in combination with chemotherapy using cisplatin) shows activity against Locally Advanced Head and Neck HPV Negative Squamous Cell Cancers and is safe.

Primary sponsor: European Organisation for Research and Treatment of Cancer (EORTC)
Collaborating group: TROG; Danish Head and Neck Cancer Group (DAHANCA)

TROG 12.01 (HPV) - this study aims to compare radiotherapy combined with either cetuximab or cisplatin in patients with locoregionally advanced HPV positive oropharyngeal squamous cell carcinoma (OPSCC) (located at the base of tongue or tonsil).

Primary sponsor: TROG

We are thankful to our 14,500 patients who have participated in our research. Please continue the generous support.

Tweets by @TROGfightcancer